Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 17.64
-0.74 (-4.03%)
Mar 9, 2026, 3:00 PM CST
Zhejiang Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 8,919 | 9,336 | 7,762 | 8,073 | 9,088 | 7,294 | Upgrade
|
| Other Revenue | 38.76 | 38.76 | 32.11 | 43.23 | 41.3 | 32.53 | Upgrade
|
| Revenue | 8,958 | 9,375 | 7,794 | 8,116 | 9,129 | 7,327 | Upgrade
|
| Revenue Growth (YoY) | -0.80% | 20.29% | -3.96% | -11.10% | 24.60% | 4.02% | Upgrade
|
| Cost of Revenue | 5,512 | 5,591 | 5,392 | 5,438 | 5,530 | 4,410 | Upgrade
|
| Gross Profit | 3,446 | 3,785 | 2,402 | 2,678 | 3,599 | 2,917 | Upgrade
|
| Selling, General & Admin | 1,458 | 1,678 | 1,481 | 1,312 | 1,546 | 1,537 | Upgrade
|
| Research & Development | 675.7 | 749.35 | 860.07 | 809.28 | 806.86 | 546.09 | Upgrade
|
| Other Operating Expenses | 92.42 | 96.54 | 78.43 | 69.86 | 75.17 | 73.04 | Upgrade
|
| Operating Expenses | 2,232 | 2,537 | 2,420 | 2,188 | 2,439 | 2,140 | Upgrade
|
| Operating Income | 1,214 | 1,248 | -18.15 | 489.74 | 1,160 | 777.42 | Upgrade
|
| Interest Expense | -23.39 | -26.37 | -28.34 | -33.11 | -39.54 | -46.27 | Upgrade
|
| Interest & Investment Income | 33.61 | 22.51 | 16.51 | 13.18 | 57.42 | 139.56 | Upgrade
|
| Currency Exchange Gain (Loss) | 17.82 | 17.82 | 36.59 | 66.6 | -64.31 | -38.46 | Upgrade
|
| Other Non Operating Income (Expenses) | 89.87 | 3.9 | 21.09 | -36.73 | -2.69 | -31.87 | Upgrade
|
| EBT Excluding Unusual Items | 1,332 | 1,266 | 27.7 | 499.67 | 1,111 | 800.38 | Upgrade
|
| Impairment of Goodwill | -18.68 | -18.68 | -9.23 | -8.12 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.56 | -29.6 | -28.59 | -56.51 | 51.73 | 30.48 | Upgrade
|
| Gain (Loss) on Sale of Assets | -4.4 | -5.21 | 323.57 | -1.37 | -7.95 | -23.48 | Upgrade
|
| Asset Writedown | -62.14 | -69.41 | - | - | -46.19 | -9.85 | Upgrade
|
| Other Unusual Items | 69.46 | 69.46 | 49.82 | 57.71 | 44.76 | 53.45 | Upgrade
|
| Pretax Income | 1,328 | 1,212 | 363.28 | 491.39 | 1,154 | 850.98 | Upgrade
|
| Income Tax Expense | 199.36 | 192.03 | 86.48 | 128.77 | 268.97 | 191.34 | Upgrade
|
| Earnings From Continuing Operations | 1,128 | 1,020 | 276.79 | 362.61 | 884.56 | 659.64 | Upgrade
|
| Minority Interest in Earnings | 115.58 | 140.26 | 152.85 | 176.96 | 160.76 | 57.76 | Upgrade
|
| Net Income | 1,244 | 1,161 | 429.64 | 539.57 | 1,045 | 717.4 | Upgrade
|
| Net Income to Common | 1,244 | 1,161 | 429.64 | 539.57 | 1,045 | 717.4 | Upgrade
|
| Net Income Growth | 27.21% | 170.11% | -20.37% | -48.38% | 45.71% | 109.29% | Upgrade
|
| Shares Outstanding (Basic) | 959 | 962 | 955 | 964 | 959 | 957 | Upgrade
|
| Shares Outstanding (Diluted) | 959 | 962 | 955 | 964 | 959 | 957 | Upgrade
|
| Shares Change (YoY) | 0.97% | 0.72% | -0.91% | 0.47% | 0.26% | 0.46% | Upgrade
|
| EPS (Basic) | 1.30 | 1.21 | 0.45 | 0.56 | 1.09 | 0.75 | Upgrade
|
| EPS (Diluted) | 1.30 | 1.21 | 0.45 | 0.56 | 1.09 | 0.75 | Upgrade
|
| EPS Growth | 25.99% | 168.18% | -19.64% | -48.62% | 45.33% | 108.33% | Upgrade
|
| Free Cash Flow | 1,516 | 534.15 | -162.56 | -455.39 | 197.05 | 721.37 | Upgrade
|
| Free Cash Flow Per Share | 1.58 | 0.56 | -0.17 | -0.47 | 0.20 | 0.75 | Upgrade
|
| Dividend Per Share | 0.370 | 0.370 | 0.150 | 0.170 | 0.330 | 0.230 | Upgrade
|
| Dividend Growth | 146.67% | 146.67% | -11.77% | -48.48% | 43.48% | -77.00% | Upgrade
|
| Gross Margin | 38.47% | 40.37% | 30.82% | 33.00% | 39.43% | 39.81% | Upgrade
|
| Operating Margin | 13.55% | 13.31% | -0.23% | 6.03% | 12.71% | 10.61% | Upgrade
|
| Profit Margin | 13.89% | 12.38% | 5.51% | 6.65% | 11.45% | 9.79% | Upgrade
|
| Free Cash Flow Margin | 16.93% | 5.70% | -2.09% | -5.61% | 2.16% | 9.84% | Upgrade
|
| EBITDA | 1,818 | 1,903 | 706.04 | 1,171 | 1,747 | 1,281 | Upgrade
|
| EBITDA Margin | 20.30% | 20.30% | 9.06% | 14.42% | 19.14% | 17.49% | Upgrade
|
| D&A For EBITDA | 604.19 | 655.62 | 724.19 | 680.81 | 586.79 | 503.81 | Upgrade
|
| EBIT | 1,214 | 1,248 | -18.15 | 489.74 | 1,160 | 777.42 | Upgrade
|
| EBIT Margin | 13.55% | 13.31% | -0.23% | 6.03% | 12.71% | 10.61% | Upgrade
|
| Effective Tax Rate | 15.01% | 15.84% | 23.81% | 26.21% | 23.32% | 22.48% | Upgrade
|
| Revenue as Reported | 8,958 | 9,375 | 7,794 | 8,116 | 9,129 | 7,327 | Upgrade
|
| Advertising Expenses | - | 18.46 | 21.25 | 19.59 | 21.3 | 20.8 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.